In this video, Fool.com analysts David Williamson and Max Macaluso discuss United Therapeutics and Discovery Laboratories' 15% intraday plunges. One received an FDA rejection, and the other had a familiar problem rear its ugly head. Watch and find out what this means for these stocks, their competitors, and investors.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why These 2 Biotech Stocks Are Plunging originally appeared on Fool.com.
David Williamson, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Motley Fool newsletter services recommend Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.